Seizure-induced reduction in PIP₃ levels contributes to seizure-activity and is rescued by valproic acid

Pishan Chang a, Matthew C. Walker b,⁎, Robin S.B. Williams a,**

⁎ Correspondence to: M. Walker, Department of Clinical and Experimental Epilepsy, Institute of Neurology, University College London, WC1N 3BG, UK
** Correspondence to: R.S.B. Williams, Centre for Biomedical Sciences, School of Biological Sciences, Royal Holloway University of London, Egham, TW20 0EX, UK

A B S T R A C T

Phosphatidylinositol (3–5) trisphosphate (PIP₃) is a central regulator of diverse neuronal functions that are critical for seizure progression, however its role in seizures is unclear. We have recently hypothesised that valproic acid (VPA), one of the most commonly used drugs for the treatment of epilepsy, may target PIP₃ signalling as a therapeutic mode of action. Here, we show that seizure induction using kainic acid in a rat in vivo epilepsy model resulted in a decrease in hippocampal PIP₃ levels and reduced protein kinase B (PKB/AKT) phosphorylation, measured using ELISA mass assays and Western blot analysis, and both changes were restored following VPA treatment. These findings were reproduced in cultured rat hippocampal primary neurons and entorhinal cortex–hippocampal slices during exposure to the GABA(A) receptor antagonist pentylenetetrazol (PTZ), which is widely used to generate seizures and seizure-like (paroxysmal) activity. Moreover, VPA’s effect on paroxysmal activity in the PTZ slice model is blocked by phosphatidylinositol 3-kinase (PI3K) inhibition or PIP₃ sequestration by neomycin, indicating that VPA’s efficacy is dependent upon PIP₃ signalling. PIP₃ depletion following PTZ treatment may also provide a positive feedback loop, since enhancing PIP₃ depletion increases, and conversely, reducing PIP₃ dephosphorylation reduces paroxysmal activity and this effect is dependent upon AMPA receptor activation. Our results therefore indicate that PIP₃ depletion occurs with seizure activity, and that VPA functions to reverse these effects, providing a novel mechanism for VPA in epilepsy treatment.

© 2013 The Authors. Published by Elsevier Inc. Open access under CC BY-NC-ND license.

Introduction

Despite the emergence of many new antiepileptic drugs in the last couple of decades (Bialer and White, 2010), approximately one-third of all epilepsy patients continue to have poorly controlled seizures (Kwan and Brodie, 2006). As a result, there has been considerable interest in defining the cellular and molecular changes in the brain that contribute to the occurrence of spontaneous seizures and epilepsy (Bialer et al., 2010). Understanding these will lead to therapeutic strategies not only for controlling the development of epilepsy (epileptogenesis) after a brain injury, but also for identifying new targets for treating seizures.

The phosphoinositide, phosphatidylinositol (3–5)-trisphosphate (PIP₃), contributes to cell signalling and has an important regulatory role not only in acute cellular physiology (e.g. synaptic transmission) but also in maintaining basal cellular activity (Vanhaesebroeck et al., 2012). Phosphoinositide levels are controlled by a complex range of lipid kinases and phosphatases (Andrews et al., 2007; Cantley, 2002; Di and De, 2006; Wu and Hu, 2010). In the case of PIP₃, the final step in its production is catalysed by phosphatidylinositol 3-kinase (PI3K) and the cellular effects of PIP₃ are inhibited by dephosphorylation through phosphatases, including the SH2 domain-containing inositol 5’-phosphatase 2 (SHIP2) (Andrews et al., 2007; Suwa et al., 2009) and the phosphatase and tensin homolog (PTEN). The cellular function of PIP₃ is mediated through direct binding to a wide range of proteins and the downstream regulation of the protein kinase B (PKB or AKT) signalling pathway (Andrews et al., 2007; Wu and Hu, 2010).

Several recent studies have implicated the PI3K/PKB/AKT pathway in seizure generation and epilepsy. The pro-apoptotic activity of the Bcl-2 interacting mediator of cell death (Bim) pathway is regulated by PIP₃-dependent phosphorylation of AKT, which is upregulated after seizures in animal models, and is altered in the hippocampus of patients with intractable epilepsy (Shinoda et al., 2004). The mammalian target of rapamycin (mTOR) pathway, which is a target of AKT and thus is also activated by PIP₃, plays an important role in epileptogenesis in...
models of chronic epilepsy and acute seizure activity (Buckmaster and Lew, 2011; Zeng et al., 2009; Zhang and Wong, 2012). Finally, deletion of PTEN in dentate granule cells results in spontaneous seizures and abnormal electroencephalogram (EEG) activity (Backman et al., 2001; Ljungberg et al., 2009). Therefore, PIP₃ and the phosphoinositide pathway in general, provide excellent candidate targets for regulating ictogenesis and epileptogenesis.

VPA (valproic acid, 2-propylpentanoic acid) is a commonly used broad-spectrum antiepileptic drug (Loscher, 1999) with multiple mechanisms (Balding and Geller, 1981; Boeckeler et al., 2006; Chang et al., 2010; Elphick et al., 2011; Lagace et al., 2005; Terbach and Williams, 2009). A number of these mechanisms could be explained by an action of VPA on phosphoinositides. We have recently shown that VPA rapidly attenuates the turnover of phosphoinositides in a simple biomedical model, Dictyostelium (Chang et al., 2012; Xu et al., 2007), and this predicts seizure control activity in mammalian in vitro seizure models (Chang et al., 2012, 2013). However, an established role for VPA in regulating seizure-dependent phosphoinositide turnover has yet to be established.

Here, we investigated the regulation of PIP₃ in an in vivo kainic acid induced seizure model, in an in vitro neuronal culture model for PTZ-induced burst activity and in an in vitro model of induced paroxysmal activity in ex-vivo slices using PTZ, using radio-labelled inositol, PIP₃ ELISA mass assays, and Western blot analysis. Using these readouts, we show that PIP₃ levels decrease in all these models and that VPA restores PIP₃ level, providing a novel mechanistic insight into VPA function. We further show that modulating phosphoinositide signalling regulates both paroxysmal activity and the efficacy of VPA in regulating these seizure-associated activities. Together our results indicate that PIP₃ depletion is a critical step in PTZ/kainic acid-induced seizure progression and that VPA acts on this pathway, providing a novel mechanistic target for seizure control.

Methods

Chemicals

All chemicals were provided by Sigma Pty Ltd (unless otherwise stated).

Animals

Male Sprague–Dawley rats (SD) were kept under controlled environmental conditions (24–25 °C; 50–60% humidity; 12 h light/dark cycle) with free access to food and water. All the experiments were approved by a local ethics committee, the UK home office and performed in accordance with the guidelines of the Animals (scientific procedure) Act 1986.

Kainic acid treatment to induced status epilepticus

Male Sprague–Dawley rats (300–350 mg) were given kainic acid (Tocris Biosciences) at a dose of 10 mg/kg (Gupta et al., 2002), or saline by intraperitoneal injection. Experimental animals were then monitored to determine the severity of seizures. The rating of the severity of seizures was based on the Racine scale (stage 1, mouth and facial movements; stage 2, head nodding and more severe facial and mouth movements; stage 3, forelimb clonus; stage 4, rearing and bilateral forelimb clonuses; stage 5, rearing and falling, with loss of postural control, full motor seizure) (Racine et al., 1972). Onset of seizures occurred 30–100 min after kainic acid injection. One hour after the animals reached stage 5 behavioural seizures, single doses of either saline or VPA (400 mg/kg) were separately administered intraperitoneally and 1 h after drug application, the animals were sacrificed by being placed in a CO₂ chamber (10 L volume chamber with a flow rate of 4 L/min). The hippocampi were then collected for further analysis, including PIP₃ assay (using total protein as a loading control) and Western blot analysis (as described below).

Western blot analysis

Brain tissue was homogenized by 10 up-and-down strokes of a homogenizer in 10 times the brain tissue volume of aCSF (in mM: NaCl 119, KCl 2.5, MgSO₄ 1.3, CaCl₂ 2.5, NaH₂PO₄ 1, NaHCO₃ 26.2 and glucose 16.6). After centrifugation, cells were washed with ice-cold phosphate buffered saline (PBS), followed by lysis for 5 min in ice-cold RIPA Buffer supplemented with protease (Complete mini EDTA free, Roche) and phosphatase inhibitors (PhosStop, Roche). Cell lysates were centrifuged at 12,000 g for 5 min, and equal amounts of protein supernatant (20 μg) were separated by 10% SDS-PAGE and transferred onto PVDF membrane (Immobilon®-FL transfer membrane, Millipore). Membranes were blocked with Tris-buffered saline–tween–20 (TBST) containing 5% BSA and incubated with primary antibodies (AKT and phospho-AKT(Ser473), Cell Signalling 587F11) overnight at 4 °C. After washing with TBST, membranes were incubated with secondary antibodies (IRDye 800CW Goat anti-Rabbit and IRDye 800CW Goat anti-Mouse, Odyssey) for 1 h at room temperature. After a second round of washing with TBST, the immuno-reactive bands were visualized using an Odyssey Infrared Imaging System.

\[\text{PI}(3–5)\text{P}_2 \text{ ELISA mass assay}\]

A PIP₃ ELISA mass assay (Echelon Biosciences, Inc.) was used as an independent means to determine the relative amount of PIP₃, present in treated or untreated neuronal cell cultures. For primary neuronal cultures, tissue culture media were removed from cells and the experiments were stopped by the addition of 0.5 mL of ice-cold 0.5 M TCA. For hippocampal slice experiments, brain tissue was homogenized in 10 times the brain tissue volume of aCSF by 10 up-and-down strokes of a tissue homogenizer (Dounce tissue grinder). Lipid extraction was carried out as described below, and for each condition, the PIP₃ analysis was carried out as described in the manufacturer’s instructions, with the colorimetric signal measured by a plate reader at 450 nm.

Hippocampal neuronal cultures

Neuronal cultures were prepared from the hippocampi of P0–P3 postnatal rats. Brain dissection was performed in ice-cold dissection solution (in mM: NaCl 137, 5.4 KCl, Na₂HPO₄ 0.25, KH₂PO₄ 0.44, CaCl₂ 1.3, MgSO₄ 1.0, NaHCO₃ 4.2, HEPES 5, and 20%FBS). The dissected tissue was then incubated for 10 min in 0.25% (w/v) trypsin in 37 °C and washed twice with washout solution (in mM: NaCl 137, KCl 5.4, Na₂HPO₄ 0.25, KH₂PO₄ 0.44, CaCl₂ 1.3, MgSO₄ 1.0, NaHCO₃ 4.2, HEPES 5) and dissociated by trituration in the presence of DNase (150 mg/mL). Cells were then plated on poly-l-lysine-coated 12-well plates with neurobasal A medium, containing supplement B27 (and 25 μM glutamine), and AraC (1 μM) was added to the cultures within 48 h of plating. The medium was changed once per week. Experiments were carried out 14 days after neuron cell preparation.

Cell radiolabelling and detection

Primary hippocampal cells in 12-well plates were labelled by addition of 0.1 μM myo-2-[³H]-inositol (20 Ci/mmol) (Hartmann Analytic GmbH) to the medium overnight. Cells were then washed with unlabelled medium prior experimentation. To analyse PTZ-induced activity, cells were treated with 5 mM PTZ for 20 min (Sugaya et al., 1989), followed by addition of drugs for 30 min. Following PTZ-induction and drug treatment, the reactions were terminated by replacing media with 500 μL of ice-cold 0.5 M trichloroacetic acid (TCA), cells were then scraped, collected, and cell pellets were washed twice with 5 mL of 300 μM TCA containing 1 mM EDTA.
Results

An in vivo decrease in hippocampal pSer473 AKT and PIP3 levels in a kainic acid-induced status epilepticus model is restored by VPA

To examine a role for PIP3 during seizure activity and following VPA treatment, we first employed an in vivo seizure model where status epilepticus was induced using kainic acid. In these experiments, repeated intraperitoneal injection of kainic acid (10 mg/kg) (Gupta et al., 2002) was used until animals developed stage 5 behavioural seizures, and animals were then administered with intraperitoneal VPA (400 mg/kg) or saline control, and hippocampi were removed after 1 h. As reported previously (Chang et al., 2013), VPA caused a significant reduction in behavioural seizure score, as described by the Racine scale, in these experiments (Supplementary Fig. 2). We then determined the effect of VPA on PIP3 levels in vivo, both using Western analysis to monitor the phosphorylation state of AKT and by direct monitoring of PIP3 levels using an ELISA mass assay technique.

Since PIP3 is critical for the recruitment of cytosolic AKT to the plasma membrane, enabling Thr308 phosphorylation by phosphoinositide-dependent kinase 1, and subsequent Ser473 phosphorylation by the rapamycin insensitive mTORC2 complex (Alessi et al., 1997; Apsel et al., 2008; Sarbassov et al., 2005; Stokoe et al., 1997), the phosphorylation state of AKT can be used as a readout for PIP3 levels (Huang et al., 2011). To assess the phosphorylation state of AKT during seizures and following VPA treatment, hippocampi were extracted from animals and analysed by Western blot using total AKT and pSer473 AKT antibodies (Figs. 1A, B). These experiments showed a significant decrease in AKT phosphorylation after seizure induction (49.9 ± 9.3% of control, N = 4, p = 0.045) (Figs. 1A, B). Treatment of animals during seizure activity with VPA restored AKT phosphorylation to control levels (101.0 ± 13.6% of control, N = 4, p = 0.005 compared to kainic acid treatment only). However, VPA treatment in the absence of convulsant did not significantly alter AKT phosphorylation levels (102.0 ± 5.5% of control, N = 3). These data suggest that seizure activity causes a reduction in PIP3 levels and VPA acts to block this reduction.

We then confirmed the accuracy of our Western analysis by directly measuring hippocampal PIP3 levels using a PIP3 ELISA mass assay technique (Fig. 1C). In these parallel experiments, PIP3 was extracted from in vivo hippocampal samples of treated animals and analysed, where we observed a significant decrease in PIP3 after seizure induction (69.1 ± 6.5% of control, N = 4, p = 0.003) (Fig. 1C), consistent with the decrease shown for phosphorylated AKT levels. Treatment of animals during seizure activity with VPA also restored PIP3 to control levels (111.0 ± 7.4% of control, N = 4, p = 0.005 compared to kainic acid treatment only). VPA treatment in the absence of convulsant did not significantly alter PIP3 levels (98.5 ± 4.6% of control, N = 3). These experiments indicate a decrease in vivo hippocampal PIP3 levels during kainic acid-induced seizure activity that is restored by treatment with VPA, but also indicate that VPA in the absence of such activity does not change PIP3 levels. Interestingly, separation of data derived from kainate animals treated with saline only injections (control) between animals that continued to seize 1 h post-injection and those that showed reduced seizure-like behaviour suggests that the reduction in PIP3 levels is dependent on the presence of seizure activity (Supplementary Fig. 3).

\[ \text{PIP3 levels decrease in hippocampal neurons during PTZ-induced activity and are restored by VPA} \]

In order to investigate the role of phosphoinositide turnover generally in seizure progression and as a target for VPA, we then employed an in vitro model of bursting activity, using PTZ applied to cultured rat primary hippocampal neurons. In these experiments we labelled the cultured rat primary hippocampal neurons with myo-[3H]-inositol which is incorporated into phosphoinositides (PI, PIP,
PTZ-induced bursting activity in primary cultured neurons, in a similar manner to seizure-like activity in hippocampal slices or in vivo (Sugaya et al., 1989). Repeating this approach, we observed a significant decrease in PIP$_3$ after application of PTZ (62.8 ± 3.8% of control, N = 18, p = 0.001 compared to control) (Figs. 2B, C), whereas there was no change in PI, PIP, and PIP$_2$ levels, nor in cytosolic inositol phosphates (Supplementary Fig. 4). Similar to the in vivo results, application of VPA (1 mM; a physiologically relevant level commonly used in these studies (Chang et al., 2012, 2013)), under burst-inducing conditions, restored PIP$_3$ levels to those of control (92.2 ± 7.7% of control, N = 15, p = 0.012 compared to PTZ) (Figs. 2B, C). However (as observed in the in vivo experiments), application of VPA under control conditions (in the absence of PTZ) did not change PIP$_3$ levels (106.0 ± 11.7% of control, N = 9) suggesting an effect of VPA on PIP$_3$ levels only under burst-inducing conditions.

We also repeated these experiments using the PIP$_3$ ELISA mass assay to confirm the accuracy of our $[^3]$H-labelling experiments. Here, we reproduced the cultured rat primary hippocampal neuron experiments, and exposed cells to PTZ (5 mM) in the presence or absence of VPA (Fig. 2D). Consistent with the previous experiments, administration of PTZ significantly decreased PIP$_3$ level (44.9 ± 8.7% of control, N = 4 independent experiments in triplicate, p = 0.000, compared to control). Application of VPA (1 mM) restored PIP$_3$ levels (81.9 ± 10.2% of control, N = 5 independent experiments in triplicate, p = 0.049), whereas application of VPA (1 mM) in control conditions (in the absence of PTZ) had no significant effect on PIP$_3$ level (93.0 ± 12.4% of control, N = 5 independent experiments in triplicate). As a control we confirmed that inhibition of PI3K activity (using 10 μM LY294002) (Lee et al., 2005; Workman et al., 2010) resulted in a large reduction in PIP$_3$ level (45.0 ± 6.9% of control, N = 3 independent experiments in triplicate).

**In vivo status epilepticus activity induced by kainic acid decreases Ser473 AKT phosphorylation and PIP$_3$ levels but these are restored by VPA.** Animals were induced to stage 5 (Racine) behavioural seizures using kainic acid (KA; 10 mg/kg), single doses of either saline or VPA (400 mg/kg) were then administered intraperitoneally, and hippocampi were extracted and analysed. (A) Western immunoblot assays were used to determine levels of phospho-Ser473 (pAKT) and total (tAKT) AKT protein during status epilepticus activity or following VPA treatment, and (B) summarised for control (non-induced; N = 3), control with VPA (N = 3), kainic acid (N = 4), and kainic acid with VPA (N = 4) treated animals, with pAKT normalised to tAKT levels. (C) Derived samples were also analysed by direct PIP$_3$ ELISA mass assay. Graphs show means ± SEM, with individual data point illustrated. Statistical analysis was performed by post-hoc Tukey test, following ANOVA (*p < 0.05, **p < 0.01, ***p < 0.001).

PIPs$_2$ and PIP$_3$ or cleaved from PIP$_3$ by PLC to release the inositol phosphate, InsP$_3$ (Fig. 2A). Phosphoinositides were quantified by lipid extraction and separation by thin layer chromatography (TLC) (Fig. 2B), using purified phosphoinositides as controls (Supplementary Fig. 1). Phosphoinositide turnover in these experiments was determined by measuring the change of $[^3]$H-labelling phosphoinositide distribution following application of the convulsant PTZ (5 mM) (Sugaya et al., 1989). Previous studies have shown that application of PTZ induces bursting activity in primary cultured neurons, in a similar manner to seizure-like activity in hippocampal slices or in vivo (Sugaya et al., 1989). Repeating this approach, we observed a significant decrease in PIP$_3$ after application of PTZ (62.8 ± 3.8% of control, N = 18,
VPA’s effect on paroxysmal activity control depends on PIP₃ regulation

Having reproduced these in vivo PIP₃ regulatory effects in vitro, we then asked if VPA’s efficacy at decreasing paroxysmal activity is dependent on PIP₃ regulation. To do this, we tested the efficacy of VPA on controlling paroxysmal activity following a reduction in PI3K activity (using two PI3K inhibitors; PI-103 (Bechard et al., 2012) and LY294002 (Lee et al., 2005; Workman et al., 2010)), and following sequestration of PIP₂ by neomycin (Gabev et al., 1989; Haughey et al., 1999; Lee et al., 2005). In these experiments, paroxysmal activity was induced in hippocampal slices (as previously with PTZ and elevated K⁺) for 30 min prior to exposure to PI-103 (10 μM) for 50 min with a subsequent stable baseline recording for over 20 min, prior to the addition of VPA for an additional 40 min (Fig. 4). In these experiments, VPA alone significantly decreased the frequency of epileptiform discharges (VPA only: 76.5 ± 2.2% of baseline, N = 5, p = 0.002 compared to control). However, in the presence of PI-103, VPA efficacy against PTZ-induced paroxysmal activity control was abolished (PI-103 + VPA: 109.8 ± 4.1% of baseline (PI-103 only), N = 4, p = 0.000 compared to VPA only). Similar results were observed in the presence of LY294002 (20 μM) (LY294002 + VPA: 97.8 ± 7.0% of baseline (LY294002 only), N = 4, p = 0.008 compared to VPA only). We then repeated these experiments with neomycin, a compound that sequesters PIP₂ with a high affinity (Gabev et al., 1989) and thus reduces PIP₃ production. In these experiments, neomycin (100 μM) application also blocked the paroxysmal activity control effect of VPA on the frequency of epileptiform activity (98.3 ± 1.8% of baseline (neomycin only), N = 5, p = 0.004 compared to VPA only). These results suggest that the anticonvulsant effect of VPA is dependent on modulation of PIP₃ signalling.

Inhibiting PIP₃ production or dephosphorylation in hippocampal slices alters burst discharges during PTZ treatment

We next asked whether changes in PIP₃ levels altered seizure progression. We tested the effect of the pharmacological reduction of PIP₃ levels using a specific class I PI3K inhibitor (PI-103) (Fig. 5A), in influencing the burst discharges in the in vitro PTZ-induced paroxysmal activity model. PI-103 is a pyridofuropyrimidine lead compound (Hayakawa et al., 2006), showing specificity for class IAα, β, and δ PI3K activities.
isoforms of p110 PI3K and class IB isoform p110γ, with significantly improved specificity compared to other PI3K inhibitors such as Wortmannin and LY294002 (Workman et al., 2010). Application of PI-103 (10 μM) to hippocampal slices during PTZ treatment significantly increased the frequency of burst activity to 138.9 ± 5.1% of baseline, N = 5 (DMSO control: 99.1 ± 3.0% of baseline, N = 4, p=0.005, unpaired t-test) (Figs. 5A, B, C). Since PI-103 does not induce increased burst discharges in the absence of PTZ, this suggests that a reduction in PIP3 production during paroxysmal activity results in enhanced paroxysmal activity.

Since reducing PIP3 levels enhanced paroxysmal activity, we then examined the reverse relationship, by reducing PIP3 dephosphorylation in this model using AS1949490, a selective SHIP2 (SH2 domain-containing inositol 5′-phosphatase 2) inhibitor (Suwa et al., 2009) (Fig. 5A). SHIP2 catalyzes the dephosphorylation of PIP3 to PIP2 and is strongly expressed in the mammalian brain (Dyson et al., 2005). Administration of AS1949490 (10 μM) to hippocampal slices following treatment with PTZ significantly suppressed the frequency of burst discharges to 82.7 ± 2.8% of baseline (N = 5, p = 0.01 compared to DMSO, unpaired t-test) (Figs. 5A, B, D). This result, in combination with that shown for PI-103, supports a role for PIP3 in providing an important protective role in paroxysmal activity associated with seizure progression.

**AMPA receptor activity is necessary for PIP3 depletion**

Together our data indicate a causal relationship between PIP3 depletion and paroxysmal activity (related to seizure progression), and moreover, imply that VPA’s action is dependent upon the PIP3 pathway. However, our data does not preclude a role for seizure activity itself leading to depletion of PIP3, which then further enhances the seizure activity as a positive feedback loop. To examine this, we employed two glutamate receptor antagonists, kynurenic acid, which is a broad-spectrum glutamate receptor antagonist (Perkins and Stone, 1982; Stone and Burton, 1988), and CNQX, which is a competitive AMPA/kainate receptor antagonist (Honore et al., 1988; Watkins et al., 1990); both have been shown to attenuate seizures (Baraban et al., 2005; Galvan et al., 2000; Godukhin et al., 2002) and are not expected to regulate PIP3 levels. Again using the hippocampal slice/PTZ-induced paroxysmal activity model, application of kynurenic acid (1 mM) significantly decreased the frequency of epileptiform discharges (Kyn: 67.4 ± 2.2% of baseline, N = 4, p = 0.01 compared to control) (Figs. 5A, B), and CNQX (20 μM) almost abolished the frequency of burst activity (2.0 ± 2.3% of baseline, N = 4, p = 0.00, compared to control), 20–40 min after PTZ application. Analysis of PIP3 levels in these hippocampal slice samples using the PIP3 ELISA mass assay showed that kynurenic acid (1 mM) and CNQX (20 μM) treatment
during seizure induction blocked PIP₂ reduction caused by PTZ treatment (Fig. 6C). These results indicate that AMPA receptor activity is necessary for paroxysmal activity progression and the consequent reduction in PIP₃ levels during this process.

**Discussion**

In the present study, we show that PIP₃ levels decrease following in vivo seizures induced with kainic acid and during application of the convulsant PTZ in two in vitro models, and this reduction is restored by the widely used anti-epileptic drug, VPA (Fig. 7). We show that the mechanism of VPA’s action is likely to be dependent upon the regulation of PIP₃, since blocking PIP₃ production (with pharmacological inhibitors or by sequestration of PIP₂) blocks VPA-dependent epileptiform activity control. Alterations in PIP₃ levels are likely to have an important effect on cell behaviour during seizures since we show PIP₃ regulates downstream cell signalling in the PKB/AKT pathway. Seizure-dependent PIP₃ reduction is also likely to be involved in seizure progression, since attenuating PIP₃ production during PTZ-induced paroxysmal activity causes increased epileptiform activity and reduced dephosphorylation reduces this activity. Inhibiting paroxysmal activity through blocking AMPA receptors prevents PIP₃ depletion, indicating that the reduction in PIP₃ is not caused by PTZ, but rather by the generation of paroxysmal (burst) activity. This leads to a paradigm in which seizure-like activity is associated with a reduction in PIP₃, giving rise to a positive feedback amplification of this activity. These data therefore implicate, for the first time, a reduction in PIP₃ levels in neurons during paroxysmal activity as a therapeutic target for seizure control.

One important corollary of the data described here is that VPA may have specific effects only visible during seizure activity, as VPA did not affect PIP₃ levels under control conditions. This observation is consistent with previous studies that show that VPA only affects frequency facilitation of synaptic transmission in epileptic but not control animals (Chang and Walker, 2011). The impact of this is that it may be essential to employ seizure-inducing conditions in subsequent experiments to identify the primary target(s) of current treatments and to develop new therapies for seizure control.

As PIP₃ is crucial for the regulation of neuron excitability via multiple mechanisms (Vanhaesebroeck et al., 2012), there are a range of means by which a reduction in PIP₃ could be involved in seizure activity. During receptor-stimulated activation, PIP₃ is asymmetrically distributed on the plasma membrane and interacts with proteins involved in cytoskeleton assembly and membrane fusion during regulated endocytosis and exocytosis (Schmid, 1997; Spiliotis and Nelson, 2003), suggesting that PIP₃ plays an important role in neurotransmission, receptor trafficking and membrane repair. PIP₃ is also crucial in the modulation of voltage-gated calcium channels (Viard et al., 2004) and directly regulates the inwardly rectifying ATP-sensitive K⁺ channels (MacGregor et al., 2002). Increasing PIP₃ production promotes translocation of ion channels to the plasma membrane, including nonspecific cation and calcium-dependent potassium channels (Kanzaki et al., 1999; Lhuillier and Dryer, 2002). Furthermore, PIP₃ regulates AMPA receptor localization
within the synapse by modulation of scaffold proteins, such that PIP3 depletion enhances mobility and dispersion of AMPA receptors in spines and reduces presynaptic activity (Arendt et al., 2010). Seizure-induced depletion of PIP3 would also interfere in homeostatic synaptic plasticity that precisely maintains basal synaptic activity (Davis, 2006; Wang et al., 2012). These wide and varied functions of PIP3 in neuronal and synaptic function, together with our demonstrated seizure-dependent reduction in PIP3, suggest that seizure activity fundamentally changes neuronal function.

One downstream target of PIP3 is the AKT/mTOR pathway and as such, PIP3 regulation is likely to play a major role in the function of this pathway. Post-seizure, AKT activation has been widely shown to be increased in both animal seizure models and in the hippocampi of epileptic patients (Shinoda et al., 2004; Zhang and Wong, 2012). Blocking pathway activation post-seizure also prevents further seizure development, thus implicating a transient increase in the pathway activation after seizures in promoting epileptogenesis (MacGregor et al., 2002; Meikle et al., 2008; Zeng et al., 2009). Suppression of post-seizure mTOR activation in other seizure models (kainate and pilocarpine) also blocks pathologic changes such as mossy fibre sprouting and synapse formation (Buckmaster and Lew, 2011; Buckmaster et al., 2009; Zeng et al., 2010) and spontaneous seizures (Zeng et al., 2010) implicating this effect as a mechanism leading to chronic epilepsy. The effect of VPA observed by us on the AKT/mTOR pathway is also supported by a range of other studies, including in vitro (Lamarre and Desrosiers, 2008; Wu and Shih, 2011) and in vivo studies (Bates et al., 2012). Thus our data suggest that seizure activity may reduce AKT/mTOR activation, which then increases post-seizure to cause pathogenic changes and epileptogenesis, and that this initial decrease is blocked by VPA thereby possibly reducing post-seizure pathway elevation. It remains to be determined if this PIP3-dependent action contributes to the neuroprotective action of VPA (Bolanos et al., 1998; Brandt et al., 2006; Li and El Mallahk, 2000; Mora et al., 1999; Wilot et al., 2007).

A range of different models are used in epilepsy research, where models often show different sensitivities to epilepsy treatments, presumably due to different molecular mechanisms. In the in vitro studies described here, we have employed PTZ, which is thought to function through regulating GABA(A) signalling, to induce paroxysmal activity associated with seizure progression (Huang et al., 2001), and have shown that this induction mechanism causes a reduction in PIP3, which is rescued by VPA. We have also induced status epilepticus in vivo using kainic acid, where kainic acid functions as a specific agonist for a class of glutamate receptors (kainate receptors) (Nadler, 1981), and have again shown a decrease in PIP3 during seizure activity and that this decrease is also rescued by VPA. These results thus suggest a common reduction in PIP3 levels during seizure-like activity following exposure to multiple independent convulsants. Subsequent studies will be necessary to investigate this mechanism in other seizure models.

Fig. 5. Epileptiform activity in rat hippocampal slices is regulated by PIP3. (A) Pharmacological regulation of PIP3 can be used to reduce the conversion of PIP2 into PIP3 via PI3K inhibition (using PI-103) and to reduce the conversion of PIP3 to PIP2 by SHIP2 inhibition (using As1949490). Red circles represent phosphates on phosphoinositides. (B) Example trace recording of epileptiform activity (burst discharges) in hippocampal slices induced by application of PTZ (PTZ 2 mM, K+ 6 mM) under control conditions (DMSO) and after inhibition of PI3K activity (PI-103, 10 μM) or SHIP2 activity (As, As1949490 10 μM). (C) Summary of the effect of PI-103 (N = 5) and (D) AS1949490 (N = 5) in PTZ-induced burst discharges in comparison with control (DMSO), where averaged data is presented from 20 to 40 min post-treatment. Graphs show means ± SEM, with individual data point illustrated. Statistical analysis was performed by unpaired Student’s t-tests (*p < 0.05, **p < 0.001). Quantification of washout epileptiform activity is shown in Supplementary Fig. 6.
and to determine if this PIP₃ rescue is related to the anti-epileptogenic effect of VPA (Bolanos et al., 1998; Brandt et al., 2006).

VPA provides a range of therapeutic roles in addition to seizure control, including bipolar disorder and migraine prophylaxis (Terbach and Williams, 2009). It is currently unclear if the mechanism of action for VPA identified here is common to these conditions. Recent studies in a simple biomedical model system (Chang et al., 2012; Xu et al., 2007) suggest that a VPA-dependent attenuation of phosphoinositides is not associated with a decrease in cytosolic inositol levels. This site of action contrasts with the function of VPA in bipolar disorder treatment (Eickholt et al., 2005) where VPA is thought to act through a cytosolic mechanism in the depletion of inositol phosphates (Berridge et al., 1989; Terbach and Williams, 2009), possibly through the indirect inhibition of de novo inositol synthesis (Eickholt et al., 2005; Shaltiel et al., 2007; Vaden et al., 2001).

We have therefore shown for the first time an effect of seizure activity on PIP₃ levels and that restoring these levels may have an anti-seizure effect. Moreover, targeting this pathway with VPA reduces paroxysmal activity. These findings suggest a novel approach to the treatment of seizures and potentially other conditions for which VPA is effective such as migraine and bipolar disorder.

Supplementary data to this article can be found online at http://dx.doi.org/10.1016/j.nbd.2013.10.017.

Acknowledgments

We gratefully acknowledge an NC3Rs grant G0ss900775 to RSBW and MW.

References

Alessi, D.R., James, S.R., Downes, C.P., Holmes, A.B., Gaffney, P.R., Reese, C.B., Cohen, P., 1997. Characterization of a 3-phosphoinositide-dependent protein kinase which phosphorylates and activates protein kinase B. Curr. Biol. 7, 261–269.

Andrews, S., Stephens, L.R., Hawkins, P.T., 2007. PI3K class IB pathway. Sci. STKE 2007, cm2.
Apsel, B., Blair, J.A., Gonzalez, B., Nazif, T.M., Feldman, M.E., Al泽stein, B., Hoffman, R., Williams, R.L., Shokat, K.M., Knight, Z.A., 2008. Targeted polypharmacology: discovery of dual inhibitors of tyrosine and phosphoinositide kinases. Nat. Chem. Biol. 4, 691–699.

Arendt, K.L., Royo, M., Fernández-Morale, M., Knof, S., Petrok, C.N., Martens, J.R., Esteban, J.A., 2010. PIP3 controls synaptic function by maintaining AMPA receptor clustering at the postsynaptic membrane. Nat. Neurosci. 13, 36–44.

Armand, V., Louvet, J., Punnin, R., Heinemann, U., 1998. Effects of new valproate derivatives on epileptiform discharges induced by pentyleneetetrazole or low Mg2+ in rat entorhinal cortex–hippocampus slices. Epilepsy Res. 32, 345–355.

Baeman, S.A., Szabo, V., Suzuki, A., Haight, J., Ella, A., Prenot, J., Tsao, M.S., Shannon, P., Bolon, B., Ivory, C.O., Mak, T.W., 2001. Deletion of Pten in mouse brain causes seizures, ataxia and defects in some size resembling Hermansut-Duclot disease. Nat. Genet. 29, 396–403.

Balder, B.P., Miller, H.M., 1981. Sodium valproate enhancement of γ-aminobutyric acid (GABA) inhibition: electrophysiological evidence for anticonvulsant activity. J. Pharmacol. Exp. Ther. 217, 445–450.

Baraban, S.C., Taylor, M.R., Castro, P.A., Baier, H., 2005. Pentyleneetetrazol induced changes in zebrafish behavior, neural activity and c-fos expression. Neuroscience 131, 759–768.

Bates, R.C., Stith, B.J., Stevens, K.E., 2012. Chronic central administration of valproic acid: increased pro-survival phospho-proteins and growth cone associated proteins with no behavioral pathology. Pharmacol. Biochem. Behav. 103, 237–244.

Bechar, M., Trost, R., Singh, A.M., Dalton, S., 2012. Frat is a phosphatidylinositol 3-kinase/Akt-regulated determinant of glycygen synthase kinase 3β subcellular localization in pluripotent cells. Mol. Cell. Biol. 32, 288–296.

Berridge, M.J., Downes, C.P., Hanley, M.R., 1989. Neural and developmental actions of calcium: a unifying hypothesis. Cell 59, 411–419.

Bialer, M., Johannessen, S.I., Levy, R.H., Perucca, E., Tomson, T., White, H.S., 2010. Progress and challenges in the development of antiepileptic drugs. Nat. Rev. Drug Discov. 9, 68–79.

Bolanos, A.R., Sarkisian, M., Yang, Y., Hori, A., Koizumi, T., Ohishi, T., Okada, M., Ohba, M., Tsukamoto, S., Parker, P., Workman, P., Waterfield, M., 2006. Synthesis and biological evaluation of 4-morpholin-2-phenylquinazolines and related derivatives as novel P2E kinase p110Dalpha inhibitors. Bioorg. Med. Chem. 14, 6847–6858.

Bennett, U., Haddad, Z.R., Mortimore, H., Koizumi, T., Ohishi, T., Okada, M., Ohba, M., Tsukamoto, S., Parker, P., Workman, P., Waterfield, M., 2006. Synthesis and biological evaluation of 4-morpholin-2-phenylquinazolines and related derivatives as novel P2E kinase p110Dalpha inhibitors. Bioorg. Med. Chem. 14, 6847–6858.

Bennett, U., Haddad, Z.R., Mortimore, H., Koizumi, T., Ohishi, T., Okada, M., Ohba, M., Tsukamoto, S., Parker, P., Workman, P., Waterfield, M., 2006. Synthesis and biological evaluation of 4-morpholin-2-phenylquinazolines and related derivatives as novel P2E kinase p110Dalpha inhibitors. Bioorg. Med. Chem. 14, 6847–6858.

Bennett, U., Haddad, Z.R., Mortimore, H., Koizumi, T., Ohishi, T., Okada, M., Ohba, M., Tsukamoto, S., Parker, P., Workman, P., Waterfield, M., 2006. Synthesis and biological evaluation of 4-morpholin-2-phenylquinazolines and related derivatives as novel P2E kinase p110Dalpha inhibitors. Bioorg. Med. Chem. 14, 6847–6858.

Bennett, U., Haddad, Z.R., Mortimore, H., Koizumi, T., Ohishi, T., Okada, M., Ohba, M., Tsukamoto, S., Parker, P., Workman, P., Waterfield, M., 2006. Synthesis and biological evaluation of 4-morpholin-2-phenylquinazolines and related derivatives as novel P2E kinase p110Dalpha inhibitors. Bioorg. Med. Chem. 14, 6847–6858.

Bennett, U., Haddad, Z.R., Mortimore, H., Koizumi, T., Ohishi, T., Okada, M., Ohba, M., Tsukamoto, S., Parker, P., Workman, P., Waterfield, M., 2006. Synthesis and biological evaluation of 4-morpholin-2-phenylquinazolines and related derivatives as novel P2E kinase p110Dalpha inhibitors. Bioorg. Med. Chem. 14, 6847–6858.

Bennett, U., Haddad, Z.R., Mortimore, H., Koizumi, T., Ohishi, T., Okada, M., Ohba, M., Tsukamoto, S., Parker, P., Workman, P., Waterfield, M., 2006. Synthesis and biological evaluation of 4-morpholin-2-phenylquinazolines and related derivatives as novel P2E kinase p110Dalpha inhibitors. Bioorg. Med. Chem. 14, 6847–6858.

Bennett, U., Haddad, Z.R., Mortimore, H., Koizumi, T., Ohishi, T., Okada, M., Ohba, M., Tsukamoto, S., Parker, P., Workman, P., Waterfield, M., 2006. Synthesis and biological evaluation of 4-morpholin-2-phenylquinazolines and related derivatives as novel P2E kinase p110Dalpha inhibitors. Bioorg. Med. Chem. 14, 6847–6858.

Bennett, U., Haddad, Z.R., Mortimore, H., Koizumi, T., Ohishi, T., Okada, M., Ohba, M., Tsukamoto, S., Parker, P., Workman, P., Waterfield, M., 2006. Synthesis and biological evaluation of 4-morpholin-2-phenylquinazolines and related derivatives as novel P2E kinase p110Dalpha inhibitors. Bioorg. Med. Chem. 14, 6847–6858.

Bennett, U., Haddad, Z.R., Mortimore, H., Koizumi, T., Ohishi, T., Okada, M., Ohba, M., Tsukamoto, S., Parker, P., Workman, P., Waterfield, M., 2006. Synthesis and biological evaluation of 4-morpholin-2-phenylquinazolines and related derivatives as novel P2E kinase p110Dalpha inhibitors. Bioorg. Med. Chem. 14, 6847–6858.

Bennett, U., Haddad, Z.R., Mortimore, H., Koizumi, T., Ohishi, T., Okada, M., Ohba, M., Tsukamoto, S., Parker, P., Workman, P., Waterfield, M., 2006. Synthesis and biological evaluation of 4-morpholin-2-phenylquinazolines and related derivatives as novel P2E kinase p110Dalpha inhibitors. Bioorg. Med. Chem. 14, 6847–6858.

Bennett, U., Haddad, Z.R., Mortimore, H., Koizumi, T., Ohishi, T., Okada, M., Ohba, M., Tsukamoto, S., Parker, P., Workman, P., Waterfield, M., 2006. Synthesis and biological evaluation of 4-morpholin-2-phenylquinazolines and related derivatives as novel P2E kinase p110Dalpha inhibitors. Bioorg. Med. Chem. 14, 6847–6858.

Bennett, U., Haddad, Z.R., Mortimore, H., Koizumi, T., Ohishi, T., Okada, M., Ohba, M., Tsukamoto, S., Parker, P., Workman, P., Waterfield, M., 2006. Synthesis and biological evaluation of 4-morpholin-2-phenylquinazolines and related derivatives as novel P2E kinase p110Dalpha inhibitors. Bioorg. Med. Chem. 14, 6847–6858.
Terbach, N., Williams, R.S., 2009. Structure–function studies for the panacea, valproic acid. Biochem. Soc. Trans. 37, 1126–1132.

Vaden, D.L., Ding, D., Peterson, B., Greenberg, M.L., 2001. Lithium and valproate decrease inositol mass and increase expression of the yeast INO1 and INO2 genes for inositol biosynthesis. J. Biol. Chem. 276, 15466–15471.

Vanhasebroeck, B., Stephens, L., Hawkins, P., 2012. PI3K signalling: the path to discovery and understanding. Nat. Rev. Mol. Cell Biol. 13, 195–203.

Viard, P., Butcher, A.J., Halet, G., Davies, A., Nurnberg, B., Heblight, F., Dolphin, A.C., 2004. PI3K promotes voltage-dependent calcium channel trafficking to the plasma membrane. Nat. Neurosci. 7, 939–946.

Wang, G., Gilbert, J., Mao, H.Y., 2012. AMPA receptor trafficking in homeostatic synaptic plasticity: functional molecules and signaling cascades. Neural Plast. 2012, 825364.

Wilot, L.C., Bernardi, A., Frozza, R.J., Marques, A.L., Cimarosti, H., Salbego, C., Rocha, E., Battastini, A.M., 2007. Lithium and valproate protect hippocampal slices against ATP-induced cell death. Neurochem. Res. 32, 1539–1546.